Early T-cell precursor (ETP) acute lymphoblastic leukemia
Conditions
Interventions
Experimental group:The V-HAG regimen included venetoclax(orally once daily,100 mg day 1, 200 mg on day 2,400mg from day 3 to day 14. If more than 5% of the blast cells in the bone marrow were present
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
14 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged > 14 years; 2. Newly diagnosed Early T-cell precursor (ETP) acute lymphoblastic leukemia; 3. ECOG 0-2; 4. Expected survival >= 2 months; 5. During the screening period, there is no abnormal organ function that restricts the use of this regimen; 6. Understand and comply with all test protocol requirements.
Exclusion criteria
Exclusion criteria: 1. Difficulties in the administration of oral medication or malabsorption syndrome; 2. Abnormal organ function that restricts the use of this regimen; 3. LVEF 1.5 ULN (normal upper limit); ALT, AST or ALP > 5ULN; Serum creatinine > 1.5 ULN; 6. HIV positive; 7. General condition is not suitable for chemotherapy; 8. Inability to understand or follow research protocols; 9. Subjects who received a potent or moderately potent CYP3A inducer/inhibitor within the 7 days prior to initiation of study therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission(CR)+CR with incomplete blood count recovery(CRi) after first induction; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;event-free survival;Overall CR/CRi;Safety;minimal residual disease,MRD; | — |
Countries
China
Contacts
Public ContactJie Jin
The First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed